Chugai Pharmaceutical Co (CUP) Stock Price & Analysis
CUP Stock Chart & Stats
- Day’s Range
- EUR 38.34 - EUR 38.41
- 52-Week Range
- EUR 33.52 - EUR 56.26
- Previous Close
- EUR 37.50
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 63.59B
- Enterprise Value
- EUR 9.39T
- Total Cash (Recent Filing)
- EUR 869.00B
- Total Debt (Recent Filing)
- EUR 16.14B
- Price to Earnings (P/E)
- 22.3
- Beta
- 0.68
- Next Earnings
- Feb 04, 2027 (Est.)
- EPS Estimate
- 0.44
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.14%
Bulls Say, Bears Say
Bulls Say
High Profitability
Chugai’s exceptionally high gross, operating, and net margins indicate strong pricing power and an attractive product mix. This profitability provides substantial resources to fund research, commercial expansion, and shareholder returns while supporting resilience through changes in product demand.
Conservative Balance Sheet
Minimal leverage and strong equity growth give Chugai considerable financial flexibility without dependence on borrowing. High returns on equity show that the company is using its capital efficiently, strengthening its ability to fund pipeline investment and withstand industry volatility.
Pipeline And Product Momentum
Divarasib’s positive Phase III efficacy and planned regulatory filing add a potentially important oncology growth driver beyond the existing portfolio. Combined with multiple advancing projects, this supports longer-term product renewal and expands Chugai’s strategic pipeline.
Bears Say
Pricing And Generic Pressure
Drug price revisions and generic competition can structurally erode revenue and margins for established products in Japan. These pressures may require continued launches and innovation merely to offset declines, increasing the importance of successful pipeline execution for sustained growth.
Free Cash Flow Growth Decline
Although absolute cash generation remains strong, the recent decline in free cash flow growth indicates that more cash is being absorbed by investment or working-capital movements. If sustained, this could reduce funding flexibility for development, licensing, and shareholder distributions.
Pipeline Attrition
Discontinuing a clinical program removes a potential future revenue source and highlights the scientific uncertainty inherent in drug development. Repeated late-stage setbacks could increase reliance on existing products and raise the execution burden on the remaining pipeline.
CUP FAQ
What was Chugai Pharmaceutical Co’s price range in the past 12 months?
What is Chugai Pharmaceutical Co’s market cap?
When is Chugai Pharmaceutical Co’s upcoming earnings report date?
How were Chugai Pharmaceutical Co’s earnings last quarter?
Is Chugai Pharmaceutical Co overvalued?
Does Chugai Pharmaceutical Co pay dividends?
What is Chugai Pharmaceutical Co’s EPS estimate?
How many shares outstanding does Chugai Pharmaceutical Co have?
What happened to Chugai Pharmaceutical Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Chugai Pharmaceutical Co?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Osamu Okuda
- Employees
- 5,104
- Website
- www.chugai-pharm.co.jp
- Address
- Nihonbashi Mitsui Tower, Tokyo, SH, 103-8324, JP
Chugai Pharmaceutical Co (CUP) Earnings & Revenues
CUP Company Deck
CUP Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Revenue and core operating profit grew substantially, the company expects to exceed its full-year forecast, overseas products and royalties performed well, and the pipeline delivered approvals, filings, positive clinical readouts, and important progress for Hemlibra and Divarasib. The main challenges were pricing and generic pressure, higher costs, one-time domestic shipment timing, discontinued GYM329 obesity and LUNA18 programs, selected product declines, and reduced cash following large tax and special dividend payments. Highlights significantly outweighed lowlights.
View all DE:CUP earnings summariesCUP Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 4 | 6 |
| Technical Analysis | 2 | 4 | 4 |
| Moving Averages | 10 | 0 | 2 |